Recent studies have found that the OGR1 antagonist GPR68-I and GPR4 antagonist Compound 13 can reduce the severity of intestinal inflammation in mouse colitis models, and targeting OGR1 with small molecule inhibitors may be a new therapeutic approach for the treatment of IBD (Sanderlin et al., 2019; de Vallière et al., 2021). The gene discussed is GPR68; the disease is inflammatory bowel disease.